magnesium L-lactate dehydrate (MLD10) / Pharmalyte Solutions - LARVOL DELTA

Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy (MTCS 2023) - "When using 4 Gy per fraction to either 60 Gy or 72 Gy, maintaining lung V20<18.0% may be a reasonable goal to minimize the risk grade ≥2 radiation pneumonitis. MLD<10.8 Gy and V5<42.0% could be considered as lower-priority constraints as well. Further research will be needed to externally validate these dose constraints prior to implementation in clinical practice or clinical trial planning guidelines"

Inflammation • Oncology • Pneumonia • Thoracic Cancer

MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Pharmalyte Solutions LLC | Trial completion date: Jan 2022 ➔ Apr 2028

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dose-volume predictors of radiation pneumonitis following thoracic hypofractionated radiotherapy. (PubMed, Pract Radiat Oncol) - "To minimize the risk of grade ≥2 radiation pneumonitis when delivering 4 Gy per fraction at either 60 Gy or 72 Gy, it is advisable to maintain lung V20<17.7%. MLD<10.6 Gy and V5<41.3% can also be considered as lower-priority constraints. However, further validation is necessary before incorporating these constraints into clinical practice or trial planning guidelines."

Journal • Inflammation • Oncology • Pneumonia • Thoracic Cancer

Impact of pretreatment clinical factors and DVH parameters on radiation pneumonitis and survival after intensity-modulated radiotherapy for lung cancer. (ASCO 2022) - "The independent significant risk factors of radiation pneumonitis were V20, V5 and MLD. In addition, the V20 and V5 of the ipsilateral lung should be more strictly limited to less than 28% and 51% when determining radiotherapy especially in this era of immunotherapy. Some blood indexes of low nutritional status were very important to determine the occurrence of high-risk radiation pneumonitis."

Clinical • Inflammation • Lung Cancer • Oncology • Pneumonia • Solid Tumor

Dose-Response Relationship Between Intracoronary Acetylcholine and Minimal Lumen Diameter in Coronary Endothelial Function Testing of Women and Men With Angina and No Obstructive Coronary Artery Disease. (PubMed, Circ Cardiovasc Interv) - "Women and men appear to have different responses to Ach during endothelial function testing. In addition to having a greater response to intracoronary Ach at all doses, men also demonstrate an Ach-MLD dose-response relationship with doses up to 200 μg, while women have minimal change in MLD with doses above 50 µg. An incremental dosing regimen during endothelial function testing appears to improve the diagnostic utility of the test and should be adjusted based on the sex of the patient."

Clinical • Journal • Cardiovascular • Coronary Artery Disease

MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2; N=200; Not yet recruiting; Sponsor: Pharmalyte Solutions LLC; N=60 ➔ 200; Trial completion date: Apr 2019 ➔ Jan 2022; Trial primary completion date: Mar 2019 ➔ Nov 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date